Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
U.S. stock CFD derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
Co-Diagnostics Names New CFO and CSO
Tuesday was a busy day in the upper managerial ranks of Co-Diagnostics (CODX +38.39%). The molecular diagnostics specialist appointed both a new CFO and a new chief science officer (CSO).
The former is Brian Brown, who replaces current office holder Reed Benson. Brown has served in a range of financial positions in his career, including a more than 10-year stint at Sportsman's Warehouse, where he was director of finance for most of that time.
The company said Benson will remain with it as a general counsel.
Image source: Getty Images.
Co-Diagnostics' new CSO is Jesse Montgomery, who was previously its senior vice president of biochemistry, a position he took up last September. He originally joined Co-Diagnostics that June as its vice president of research.
Montgomery replaces Brent Satterfield, the company's founder. Similar to outgoing CFO Benson, Satterfield will also stay with Co-Diagnostics. In his case, he will serve as the head of its scientific advisory board.
In the press release heralding the executive changes, Co-Diagnostics said that they "[follow] significant growth in the past year and in anticipation of additional growth in the future." On the back of sudden prominence related to its COVID-19 diagnostic solutions, the company's stock has been on fire, rising by nearly 1,000% in 2020.
With that kind of performance, investor expectations are high, and the company appears to be gearing up to meet them.
That said, its shares fell by over 5% on Tuesday, against the slight (0.1%) gain of the S&P 500 index.